Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature

Hrudka, Jan; Lawrie, Kateřina; Waldauf, Petr; Ciprová, Vanda; Moravcová, Jana; Matěj, Radoslav

doi:10.1007/s00428-020-02830-8

Cited by 26 publications

(36 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent paper also correlated PD-L1 expression with the TP53 inactivation [123]. Nevertheless, this evidence was not confirmed by a later study, suggesting that this association is still controversial and should be better investigated [124]. In addition to PD-L1 expression, several monocytes/macrophages markers were analyzed in different works.…”

Section: Undifferentiated Carcinoma With Osteoclast-like Giant Cells Carcinomamentioning

confidence: 91%

See 1 more Smart Citation

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology

Bazzichetto

Luchini

Cognetti

et al. 2020

IJMS

View full text Add to dashboard Cite

To date, pancreatic cancer is still one of the most lethal cancers in the world, mainly due to the lack of early diagnosis and personalized treatment strategies. In this context, the possibility and the opportunity of identifying genetic and molecular biomarkers are crucial to improve the feasibility of precision medicine. In 2019, the World Health Organization classified pancreatic ductal adenocarcinoma cancer (the most common pancreatic tumor type) into eight variants, according to specific histomorphological features. They are: colloid carcinoma, medullary carcinoma, adenosquamous carcinoma, undifferentiated carcinoma, including also rhabdoid carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, hepatoid carcinoma, and signet-ring/poorly cohesive cells carcinoma. Interestingly, despite the very low incidence of these variants, innovative high throughput genomic/transcriptomic techniques allowed the investigation of both somatic and germline mutations in each specific variant, paving the way for their possible classification according also to specific alterations, along with the canonical mutations of pancreatic cancer (KRAS, TP53, CDKN2A, SMAD4). In this review, we aim to report the current evidence about genetic/molecular profiles of pancreatic cancer variants, highlighting their role in therapeutic and clinical impact.

show abstract

Section: Undifferentiated Carcinoma With Osteoclast-like Giant Cells Carcinomamentioning

confidence: 91%

“…Furthermore, PD-L1 levels define the patient's prognosis. Indeed, UCOGC PD-L1 negative patients show a longer survival than UCOGC PD-L1 positive or PDAC (regardless of PD-L1 status) [124]. A recent paper also correlated PD-L1 expression with the TP53 inactivation [123].…”

Section: Undifferentiated Carcinoma With Osteoclast-like Giant Cells Carcinomamentioning

confidence: 94%

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology

Bazzichetto

Luchini

Cognetti

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that PD-L1 is expressed in neoplastic cells of about 60–80% of UC-OGC cases, and particularly in cases with an associated pancreatic ductal adenocarcinoma. Expression of PD-L1 is associated with poor prognosis ( 30 , 73 , 74 ). The possible mechanism underlying the aggresive behavior of PD-L1 positive UC-OGC might be the inhibition of anti-tumor immunity by PD-L1, allowing neoplastic cells to escape the cytotoxic activity of T-lymphocytes ( 73 ).…”

Section: Prognosis and Treatmentmentioning

confidence: 99%

“…Expression of PD-L1 is associated with poor prognosis ( 30 , 73 , 74 ). The possible mechanism underlying the aggresive behavior of PD-L1 positive UC-OGC might be the inhibition of anti-tumor immunity by PD-L1, allowing neoplastic cells to escape the cytotoxic activity of T-lymphocytes ( 73 ). This hypothesis is supported by the fact that UC-OGC contains numerous inflammatory cells ( 1 ); UC-OCG contains significantly more CD3 + and CD8 + tumor-infiltrating lymphocytes/mm 2 than conventional pancreatic ductal adenocarcinoma ( 73 ).…”

Section: Prognosis and Treatmentmentioning

confidence: 99%

“…The possible mechanism underlying the aggresive behavior of PD-L1 positive UC-OGC might be the inhibition of anti-tumor immunity by PD-L1, allowing neoplastic cells to escape the cytotoxic activity of T-lymphocytes ( 73 ). This hypothesis is supported by the fact that UC-OGC contains numerous inflammatory cells ( 1 ); UC-OCG contains significantly more CD3 + and CD8 + tumor-infiltrating lymphocytes/mm 2 than conventional pancreatic ductal adenocarcinoma ( 73 ). These insights might have potential impact for therapeutic strategies and suggest a strong need for a clinical trial of immune checkpoint immunotherapy in patients with advanced PD-L1 positive UC-OGC.…”

Section: Prognosis and Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Undifferentiated Pancreatic Carcinoma With Osteoclast-Like Giant Cells: What Do We Know So Far?

et al. 2021

View full text Add to dashboard Cite

Undifferentiated carcinoma of the pancreas is an aggressive but rare tumor for which several other terms have been used to describe its histological appearance. In addition, as osteoclast-like giant cells may accompany undifferentiated carcinoma of the pancreas, the WHO Classification distinguishes undifferentiated carcinoma with osteoclast-like giant cells (UC-OGC) from plain undifferentiated carcinoma since there are a few histopathological and clinical differences. UC-OGC was initially thought to be associated with worse prognosis compared to invasive ductal pancreatic adenocarcinoma, since it is often unresectable at diagnosis and tends to recur rapidly even if completely resected. When true UC-OGGs are carefully dissected out from other anaplastic carcinomas, it becomes, however, clear that UC-OGCs do have more indolent behavior, especially the pure UC-OGCs. This mini-review summarizes the current knowledge on UC-OGC.

show abstract

Undifferentiated carcinoma with osteoclast‐like giant cells of pancreas on cytology: A case report with review of literature

Gupta¹,

Goyal²,

Chaudhary³

et al. 2022

Diagnostic Cytopathology

View full text Add to dashboard Cite

Undifferentiated carcinoma with osteoclast‐like giant cells (UC‐OGC) is a rare malignant neoplasm accounting for <1% of pancreatic masses. Very few case reports and small series have described the cytomorphological features of this entity. We report a case of UC‐OGC arising in the pancreas presenting with liver metastasis in a 56‐year‐old man diagnosed by guided fine‐needle aspiration cytology (FNAC). A characteristic biphasic pattern comprising of malignant mononuclear cells with scattered bland giant cells were the hallmark features for cytological diagnosis. Our case along with review of cytology literature emphasize the utility of FNAC and the cell block in the diagnosis and management of this rare entity.

show abstract

Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature

Cited by 26 publications

References 37 publications

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology

Undifferentiated Pancreatic Carcinoma With Osteoclast-Like Giant Cells: What Do We Know So Far?

Undifferentiated carcinoma with osteoclast‐like giant cells of pancreas on cytology: A case report with review of literature

Contact Info

Product

Resources

About